ASCO24 Day 3 Highlights by The Oncology Brothers

The Oncology Brothers shared on X:

“1. DB06 TDxD HR+ metastatic breast cancer (mBC)

2. TransMet Liver transplant in metastatic colorectal cancer (mCRC)

3. Collision Surgery/Ablation in mCRC

4. ESOPEC (UpperGI)

5. LAURA Consolidation (mNSCLC)

6. ADRIATIC Durva (LS-SCLC)

7. ReachPC: Palliative Oncology

8. NADINA (Melanoma)

1. DestinyBreast06:

• Phase III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow
• Majority of HR+ (85%) in this category
• PFS 13.2 vs 8.1 mos (HR 0.62)
• AEs: ILD, Fatigue, and Nausea
• Should I even test for Her2?

2. TransMet:

• Chemo plus Liver transplant vs Chemo in metastatic liver confined CRC
• mFU of 59 months, PFS 57% vs 13% (HR: 0.37)
• OS: 73% vs 9% (HR: 0.16)
• Importance of Multi-D for liver confined disease

3. COLLISION:

• Surgery vs Ablation in Liver confined/resectable metastatic CRC
• No OS difference with thermal ablation or surgery for small Mets
• Medium size 14mm and 2 lesions
• Importance of Multi-D but in the right patient, they can stay close to home .

4. ESOPEC:

• Phase III, perioperative FLOT vs NeoAdj Chemoradiation in adeno-esophageal carcinoma:
• pCR FLOT (17% vs 10%)
• Much pCR than original CROSS (23%)
• 3 yearr OS: 57.4% vs 50.7% (mOS: 66 months vs 37months)
• FLOT better in all subgroups (benefit limited in N0).
• What about CM577?

5. LAURA:

• Phase III, Indefinite Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
• New SoC
• Increase of PFS with Osi, 39.1 months vs 5.6 months (HR 0.16)
• OS Pending –
• 2 year PFS: 65% vs 13%
• High cross over/received osi at progression
• ≥Gr 3 AEs: 35% vs 12%

6. ADRIATIC:

• Phase III, durvalumab ± Tremi for 2 years after concurrent ChemoXRT limited stage small cell lung cancer
• New SoC
• Increase of OS with durva 55.9months vs 33.4 months (HR 0.73)
• Increase of PFS (HR: 0.76)
• Increase of AEs with Durvalumab

7. ReachPC:

• Role of Palliative Oncology using teleheath in Lung Cancer, n=1250
• Collaboration with palliative oncology is critical
• No QoL difference seen via telehealth or in person
• Similar satisfaction by both means

8. NADINA:

• Phase III, n = 432, NeoAdj Ipi/Nivo vs. Adj Nivo in Stage III melanoma
• New SoC
• 1 year EFS: 83.7% vs 57.2%
• Difference in restricted survival was 8 months (HR: 0.32)
• 59% major path response
• ≥Gr 3 AEs 29.7% with Ipi Nivo”

Source: Oncology Brothers/X